Subscribe
Peakstock / Shutterstock.com
9 April 2024NewsBig PharmaMuireann Bolger

US govt faces calls to green-light prostate cancer drug generics

Annual global sales of Pfizer and Astella blockbuster drug reach roughly $5 billion | Nonprofits argue the drug is sold at a price three to six times higher in the US than it’s priced in other similar high-income countries | Move to curb drug prices follows controversial march-in rights plan.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
Fed Circ affirms invalidation of two cancer treatment patents
17 August 2023   Judges uphold PTAB decision invalidating Incept patents related to use of biodegradable filler in radiation treatment | Swedish firm Palette had challenged patents through inter partes review.
Big Pharma
US refuses to compel lower prices for Pfizer and Astellas cancer drug
23 March 2023   NIH rejects petition to use “march-in” rights to allow cheaper competition | Xtandi is “widely available” to public, federal agency says.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Biotechnology
Fed Circ affirms invalidation of two cancer treatment patents
17 August 2023   Judges uphold PTAB decision invalidating Incept patents related to use of biodegradable filler in radiation treatment | Swedish firm Palette had challenged patents through inter partes review.
Big Pharma
US refuses to compel lower prices for Pfizer and Astellas cancer drug
23 March 2023   NIH rejects petition to use “march-in” rights to allow cheaper competition | Xtandi is “widely available” to public, federal agency says.

More on this story

Biotechnology
Fed Circ affirms invalidation of two cancer treatment patents
17 August 2023   Judges uphold PTAB decision invalidating Incept patents related to use of biodegradable filler in radiation treatment | Swedish firm Palette had challenged patents through inter partes review.
Big Pharma
US refuses to compel lower prices for Pfizer and Astellas cancer drug
23 March 2023   NIH rejects petition to use “march-in” rights to allow cheaper competition | Xtandi is “widely available” to public, federal agency says.

More features

GSK triumphs in EPO appeal, revoking Pfizer patent
‘We took Ravgen head-on’: How we won zero-damages and others didn't
Kathi Vidal to leave USPTO ahead of incoming Trump administration
Herbert Smith Freehills and Kramer Levin in $2bn merger talks
Teva fights for re-listing of inhaler patents at US appeals court
CRISPR patents revoked following Nobel Prize winners’ withdrawal
White & Case hires experienced litigator from A&O Shearman
President Trump 2.0: Five major areas to watch